ERBB2 and breast carcinoma: The integrative analysis of transcriptomics, proteomics, and clinical outcome in HER2-positive breast cancers who acquired resistance to lapatinib revealed EGFR/HER2 signaling was still blocked, and the blocked intensity was weakened by the upregulation of glucose metabolism and endoplasmic reticulum stress pathways [288].